Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares Core Growth Allocation ETF (AOR) vs Zoetis Inc (ZTS) Price & Performance

iShares Core Growth Allocation ETFTrade
Zoetis IncTrade

Price performance (Past 24H)

Key statistics

iShares Core Growth Allocation ETF vs Zoetis Inc — how do they compare? iShares Core Growth Allocation ETF trades at $70.1, while Zoetis Inc trades at $72.41 (market cap $31.14B). The key difference: Zoetis Inc pays a 2.81% dividend while iShares Core Growth Allocation ETF pays none, and iShares Core Growth Allocation ETF is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.

AORZTS
52-Week High
$70.12$156.76
52-Week Low
$62.26$71.91
Market Cap
$31.14B
Sector
Health
Enterprise Value
$38.70B
Dividend Yield
2.81%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares Core Growth Allocation ETF

AOR, the iShares Core Growth Allocation ETF, trades at $69.87, showing minimal daily movement. Technical indicators are bullish based on moving averages, though the RSI suggests potential overbought conditions. The fund maintains a fixed 60/40 stock/bond allocation, offering a low-cost, diversified core holding strategy with a 20 basis point fee.

The outlook for AOR is stable, providing a straightforward asset allocation tool for long-term investors. Key risks include underperformance versus pure equity indices like the S&P 500 over extended periods, as noted by financial media, and sensitivity to interest rate changes affecting the bond portion.

Zoetis Inc

Zoetis (ZTS) trades at $74.86, up 3.03% today but facing bearish technical signals with 16 sell indicators. The company reported mixed Q2 2026 results, beating EPS estimates but missing revenue expectations, while cutting full-year guidance due to softer pet healthcare demand. Strong fundamentals include a 27.69% net margin and 64.91% ROE, though valuation metrics show a P/E of 12.29 and P/S of 3.41.

The stock presents a value opportunity with analyst consensus target of $94.90 (27% upside), but faces near-term headwinds from competitive pressures and class action lawsuits. Investors should weigh strong profitability against slowing growth in companion animal segments and technical bearishness.

Returns comparison

Trailing returns across standard periods

About iShares Core Growth Allocation ETF

The fund is a fund of funds and seeks its investment objective by investing primarily in underlying funds that themselves seek investment results corresponding to their own respective underlying indexes. It generally will invest at least 80% of its assets in the component securities of its underlying index. The index measures the performance of the S&P Dow Jones Indices LLC proprietary allocation model.

Read more on AOR

About Zoetis Inc

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Read more on ZTS